

BLUE CROSS

An Independent Licensee of the Blue Cross Blue Shield Associatio

MEDICAL POLICY – 7.01.546 Spinal Cord and Dorsal Root Ganglion Stimulation

BCBSA Ref. Policy: 7.01.25

Effective Date:	Jul. 1, 2025	RELATED	MEDICAL POLICIES:
Last Revised	Jun. 23, 2025	1.01.507	Electrical Stimulation Devices
Replaces: 7.01.25		7.01.63	Deep Brain Stimulation
		7.01.574	Implantable Peripheral Nerve Stimulation for the Treatment of Chronic
			Pain and Other Conditions
		11.01.524	Site of Service: Select Surgical Procedures

Select a hyperlink below to be directed to that section.

POLICY CRITERIA | DOCUMENTATION REQUIREMENTS | CODING RELATED INFORMATION | EVIDENCE REVIEW | REFERENCES | HISTORY

Clicking this icon returns you to the hyperlinks menu above.

Introduction

Spinal cord stimulation is used to treat certain types of pain. A small device is surgically placed beneath the skin. Small amounts of electric current are sent to the spinal cord and the current interferes with the sensation of pain. This treatment has been studied for use in several different types of pain. Medical studies show that spinal cord stimulation may be effective to treat low back pain when surgery and other treatments have not helped. Medical evidence also shows it may be effective for certain other types of pain including complex regional pain syndrome. This policy discusses when spinal cord stimulation and dorsal root ganglion stimulation may be considered medically necessary.

Note: The Introduction section is for your general knowledge and is not to be taken as policy coverage criteria. The rest of the policy uses specific words and concepts familiar to medical professionals. It is intended for providers. A provider can be a person, such as a doctor, nurse, psychologist, or dentist. A provider also can be a place where medical care is given, like a hospital, clinic, or lab. This policy informs them about when a service may be covered.

Policy Coverage Criteria

We will review for medical necessity these elective surgical procedures.

We also will review the site of service for medical necessity. Site of service is defined as the location where the surgical procedure is performed, such as an off campus-outpatient hospital or medical center, an on campus-outpatient hospital or medical center, an ambulatory surgical center, or an inpatient hospital or medical center.

Site of Service for	Medical Necessity	
Elective Surgical		
Procedures		
Medically necessary sites	Certain elective surgical procedures will be covered in the most	
of service:	appropriate, safe, and cost-effective site. These are the	
Off campus-outpatient	preferred medically necessary sites of service for certain	
hospital/medical center	elective surgical procedures.	
On campus-outpatient		
hospital/medical center		
Ambulatory Surgical		
Center		
Inpatient hospital/medical	Certain elective surgical procedures will be covered in the most	
center	appropriate, safe, and cost-effective site. This site is	
	considered medically necessary only when the individual has a	
	clinical condition which puts him or her at increased risk for	
	complications including any of the following (this list may not	
	be all inclusive):	
	Anesthesia Risk	
	 ASA classification III or higher (see definition) 	
	 Personal history of complication of anesthesia 	
	 Documentation of alcohol dependence or history of 	
	cocaine use	
	 Prolonged surgery (>3 hours) 	
	Cardiovascular Risk	
	 Uncompensated chronic heart failure (NYHA class III or IV) 	
	\circ Recent history of myocardial infarction (MI) (<3 months)	
	 Poorly controlled, resistant hypertension* 	
	 Recent history of cerebrovascular accident (< 3 months) 	
	 Increased risk for cardiac ischemia (drug eluting stent 	
	placed < 1 year or angioplasty <90 days)	
	 Symptomatic cardiac arrhythmia despite medication 	
	 Significant valvular heart disease 	



Site of Service for	Medical Necessity		
Elective Surgical			
Procedures			
	Liver Risk		
	 Advance liver disease (MELD Score > 8)** 		
	Pulmonary Risk		
	 Chronic obstructive pulmonary disease (COPD) (FEV1 		
	<50%)		
	 Poorly controlled asthma (FEV1 <80% despite treatment) 		
	 Moderate to severe obstructive sleep apnea (OSA)*** 		
	Renal Risk		
	 End stage renal disease (on dialysis) 		
	• Other		
	• Morbid obesity (BMI \geq 50)		
	 Pregnancy 		
	 Bleeding disorder (requiring replacement factor, blood 		
	products, or special infusion product [DDAVP**** does not		
	meet this criterion])		
	 Anticipated need for transfusion(s) 		
	Note: * 3 or more drugs to control blood pressure		
	** https://reference.medscape.com/calculator/meld-score-end-		
	stage-liver-disease		
	*** Moderate-AHI≥15 and ≤ 30, Severe-AHI ≥30		
	****DDAVP-Deamino-Delta-D-Arginine Vasopressin (Desmopressin)		
Inpatient hospital/medical	This site of service is considered NOT medically necessary for		
center	certain elective surgical procedures when the site of service		
	criteria listed above are not met.		

Procedure	Medical Necessity	
Spinal cord stimulation	A trial with standard or high-frequency spinal cord stimulation	
trial and permanent	using a temporary stimulator may be considered medically	
placement	necessary when ALL of the following criteria are met:	
Standard spinal cord	• The treatment is used only as a last resort. Other treatment	
stimulation	modalities (pharmacological, surgical, psychological, or	
High-frequency spinal	physical, if applicable) have failed, or are judged to be	
cord stimulation	unsuitable or contraindicated	



Procedure	Medical Necessity		
Procedure	 Medical Necessity AND The individual has severe and chronic neuropathic pain of the trunk or limbs resulting from actual damage to peripheral nerves (such as failed lumbar back surgery syndrome, complex regional pain syndrome, arachnoiditis, phantom limb/stump pain, peripheral neuropathy, or painful diabetic neuropathy) AND Member has obtained clearance by a licensed psychologist, psychiatrist, or other licensed mental health professional AND No untreated drug habituation exists 		
	considered medically necessary when the above medical		
	necessity criteria for a trial spinal cord stimulator are met, and		
	at least a 3-day trial of temporary spinal cord stimulation		
Dorsal root ganglion (DRG)	A dorsal root ganglion neurostimulation trial is considered		
stimulation trial and	medically necessary for the treatment of severe and chronic		
permanent placement	pain of the trunk or limbs that is refractory to all other pain		
	 therapies when ALL of the following criteria are met: The treatment is used only as a last resort. Other treatment modalities (pharmacological, surgical, psychological, or physical, if applicable) have failed, or are judged to be unsuitable or contraindicated 		
	AND		
	• The individual has severe and chronic neuropathic pain of the trunk or limbs resulting from actual damage to peripheral nerves (such as failed lumbar back surgery syndrome, complex regional pain syndrome, arachnoiditis, phantom limb/stump pain, peripheral neuropathy, or painful diabetic neuropathy)		
	AND		
	 Member has obtained clearance by a licensed psychologist, psychiatrict or other licensed montal health professional 		
	AND		
	 No untreated drug habituation exists 		

Procedure	Medical Necessity	
	Placement of a permanent dorsal root ganglion	
	neurostimulator may be considered medically necessary when	
	the above medical necessity criteria for a trial dorsal root	
	ganglion neurostimulator are met, and there is demonstration	
	of at least a 50% reduction in pain with at least a 3-day trial of	
	temporary dorsal root ganglion stimulation	
Replacement of spinal cord	Replacement of an existing spinal cord stimulator (standard or	
stimulators or dorsal root	high-frequency) or dorsal root ganglion neurostimulator may	
ganglion neurostimulators	be considered medically necessary in only a small subset of	
	individuals when:	
	The stimulator is not working or is broken	
	OR	
	Replacement is needed because the individual's condition has	
	changed such that the current processor is inadequate or no	
	longer meets the functional needs of the individual and	
	improvement is expected with a replacement device.	
	Replacement of a functioning standard spinal cord stimulator	
	with a high-frequency spinal cord stimulator is considered not	
	medically necessary.	

Procedure	Investigational	
Spinal cord stimulation in	Spinal cord stimulation is considered investigational in all	
other situations	other situations not outlined in the Medical Necessity section	
	above, including but not limited to treatment of any of the	
	following:	
	• Central deafferentation pain (pain related to CNS damage from	
	a stroke or spinal cord injury)	
	 Nociceptive pain (pain resulting from irritation rather than damage to the nerves (see Definition of Terms) 	
	• Critical limb ischemia as a technique to forestall amputation	
	Refractory angina pectoris	
	Chronic pelvic pain (abdominal or visceral)	
	Treatment of cancer-related pain	
	Treatment of heart failure	



Documentation Requirements

The individual's medical records submitted for review should document that medical necessity criteria are met. The record should include ALL of the following:

- For TRIAL spinal cord stimulator or dorsal root ganglion neurostimulator
 - Relevant history and physical showing that the individual has severe and chronic neuropathic pain of the trunk or limbs resulting from actual damage to peripheral nerves
 - That the treatment is used only as a last resort, that individual has tried other standard treatment modalities and they were not effective or contraindicated
 - Individual has obtained clearance from a licensed psychologist, licensed psychiatrist, or other licensed mental health professional
 - The individual has no untreated drug habituation
- For PERMANENT spinal cord stimulator or dorsal root ganglion neurostimulator:
 - o All of the above listed criteria are met

AND

• There is demonstration of at least a 50% reduction in pain with at least a 3-day trial of temporary spinal cord stimulation or dorsal root ganglion neurostimulation.

Coding

Code	Description
СРТ	
0784T	Insertion or replacement of percutaneous electrode array, spinal, with integrated neurostimulator, including imaging guidance, when performed
0785T	Revision or removal of neurostimulator electrode array, spinal, with integrated neurostimulator
63650	Percutaneous implantation of neurostimulator electrode array, epidural
63655	Laminectomy for implantation of neurostimulator electrodes, plate/paddle, epidural
63661	Removal of spinal neurostimulator electrode percutaneous array(s), including fluoroscopy, when performed
63662	Removal of spinal neurostimulator electrode plate/paddle(s) placed via laminotomy or laminectomy, including fluoroscopy, when performed
63663	Revision including replacement, when performed, of spinal neurostimulator electrode percutaneous array(s), including fluoroscopy, when performed



Code	Description		
63664	Revision including replacement, when performed, of spinal neurostimulator electrode plate/paddle(s) placed via laminotomy or laminectomy, including fluoroscopy, when performed		
63685	Insertion or replacement of spinal neurostimulator pulse generator or receiver, direct or inductive coupling		
63688	Revision or removal of implanted spinal neurostimulator pulse generator or receiver		
HCPCS			
C1767	Generator, neurostimulator (implantable), nonrechargeable		
C1778	Lead, neurostimulator (implantable)		
C1787	Patient programmer, neurostimulator		
C1820	Generator, neurostimulator (implantable), with rechargeable battery and charging system		
C1822	Generator, neurostimulator (implantable), high frequency, with rechargeable battery and charging system		
C1826	Generator, neurostimulator (implantable), includes closed feedback loop leads and all implantable components, with rechargeable battery and charging system		
C1827	Generator, neurostimulator (implantable), nonrechargeable, with implantable stimulation lead and external paired stimulation controller		
C1883	Adaptor/extension, pacing lead or neurostimulator lead (implantable)		
C1897	Lead, neurostimulator test kit (implantable)		
L8679	Implantable neurostimulator, pulse generator, any type		
L8680	Implantable neurostimulator electrode, each		
L8681	Patient programmer (external) for use with implantable programmable neurostimulator pulse generator		
L8682	Implantable neurostimulator radiofrequency receiver		
L8683	Radiofrequency transmitter (external) for use with implantable neurostimulator radiofrequency receiver		
L8685	Implantable neurostimulator pulse generator, single array, rechargeable, includes extension		
L8686	Implantable neurostimulator pulse generator, single array, non-rechargeable, includes extension		
L8687	Implantable neurostimulator pulse generator, dual array, rechargeable, includes extension		

Code	Description
L8688	Implantable neurostimulator pulse generator, dual array, non-rechargeable, includes extension
L8689	External recharging system for battery (internal) for use with implantable neurostimulator, replacement only

Note: CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). HCPCS codes, descriptions and materials are copyrighted by Centers for Medicare Services (CMS).

Related Information

"Burst" neurostimulation is an alternate programming of a standard SCS device. A clinician programmer application is used to configure a standard SCS device to provide stimulation in "bursts" rather than at a constant ("tonic") rate.

The optimal level for spinal cord stimulator lead position depends on the location of pain. For low back and lower extremity pain, leads are placed at low thoracic/upper lumbar levels (T8 to L1). Cervical leads, which are placed for treatment of pain related to cervical radicular pain or upper extremity complex regional pain syndrome (CRPS), may be accessed via the mid-to upper-thoracic epidural space.

The usual levels for lead position for pain in anatomic regions are as follows:

- Neck Above C3
- Shoulder Above C5
- Hand C5, C6
- Thigh Anterior T7, T8, posterior T11 to L1
- Foot L1
- Low back T9 to T10

Definition of Terms

American Society of Anesthesiologists (ASA) Score:



ASA 1 A normal healthy patient.
ASA 2 A patient with mild systemic disease.
ASA 3 A patient with severe systemic disease.
ASA 4 A patient with severe systemic disease that is a constant threat to life.

ASA 5 A moribund patient who is not expected to survive

Arachnoiditis: An inflammation of the arachnoid, one of the linings (meninges) that surround the nerves of the brain and spinal cord, leading to disabling pain, numbness, burning and stinging like symptoms. These symptoms commonly occur in the lower back and lower extremities and may be progressive over time. It is considered a rare disorder.

Central deafferentation pain: Pain caused by a primary lesion or dysfunction of the central nervous system such as cerebrovascular lesions, multiple sclerosis or traumatic spinal cord injuries leading to a chronic burning, shooting pain, numbress or tingling within the affected body part. There may also be related sensitivity to touch as well as to temperature.

Complex Regional Pain Syndrome (CRPS): CRPS is a chronic pain condition that is thought to be caused by damage to the peripheral (nerve signaling from the brain and spinal cord to the rest of the body) and central nervous systems (the brain and spinal cord). It usually affects one limb (arm, leg, hand, or foot) often after an injury or trauma. The symptoms are excessive pain, increased sensitivity in the affected area, and may include changes in skin temperature, skin color, or swelling of the affected limb. There are two types: CRPS I (previously known as reflex sympathetic dystrophy syndrome) describes individuals without a confirmed nerve injury. CRPS II (previously known as causalgia) describes individuals with a confirmed nerve injury.

Neuropathic pain: Neuropathic pain is caused by problems with or damage to the somatosensory nervous system itself. For example, a herniated disc can compress a nerve entering the spinal cord, or phantom nerve pain can happen after a limb has been amputated. Neuropathic pain tends to be shooting or burning pain and is often chronic. Physical signs of nerve damage may be seen on examination. Placement of a spinal cord stimulator is only appropriate for the treatment of neuropathic pain.

New York Heart Association (NYHA) Classification:

Class I No symptoms and no limitation in ordinary physical activity, e.g., shortness of breath when walking, climbing stairs etc.

Class II Mild symptoms (mild shortness of breath and/or angina) and slight limitation during ordinary activity.

Class III Marked limitation in activity due to symptoms, even during less-than-ordinary activity, e.g., walking short distances (20–100 m). Comfortable only at rest.



Class IV Severe limitations. Experiences symptoms even while at rest. Mostly bedbound patients

Nociceptive Pain: Nociceptive pain happens after tissue in the body has been damaged or is inflamed. Nociceptors (pain receptors) in the tissue may be stimulated by noxious chemicals, mechanical trauma, or heat. This stimulation causes the nociceptors to fire and send an electrical signal up a sensory nerve to the brain, and the sensation of pain is felt. Nociceptive pain tends to happen suddenly, such as when a finger is cut with a knife, and the pain stops once the damage has healed.

Evidence Review

Description

Spinal cord stimulation (SCS) delivers low-voltage electrical stimulation to the dorsal columns of the spinal cord to block the sensation of pain; this is achieved through a surgically implanted SCS device, which comes equipped with a radiofrequency receiver. The neurostimulator device is also issued with a standard power source (battery) that can be implanted or worn externally. Other neurostimulators target the dorsal root ganglion.

Background

Chronic Pain

Spinal cord stimulation (SCS) has been used in a wide variety of chronic refractory pain conditions, including pain associated with cancer, failed back pain syndromes, arachnoiditis, and complex regional pain syndrome (CPRS; i.e., chronic reflex sympathetic dystrophy). There has also been interest in SCS as a treatment of critical limb ischemia, primarily in individuals who are poor candidates for revascularization and in individuals with refractory chest pain.

Spinal Cord Stimulation

SCS—also called dorsal column stimulation—involves the use of low-level epidural electrical stimulation of the spinal cord dorsal columns. The neurophysiology of pain relief after SCS is



uncertain but may be related to either activation of an inhibitory system or blockage of facilitative circuits.

SCS devices consist of several components: 1) the lead that delivers the electrical stimulation to the spinal cord; 2) an extension wire that conducts the electrical stimulation from the power source to the lead; and 3) a power source that generates the electricity. The lead may incorporate from four to eight electrodes, with eight electrodes more commonly used for complex pain patterns. There are two basic types of power source: one type, the power source (battery) can be surgically implanted or worn externally with an antenna over the receiver; the other, a radiofrequency receiver, is implanted. Totally implantable systems are most commonly used.

The individual's pain distribution pattern dictates at what level of the spinal cord the stimulation lead is placed. The pain pattern may influence the type of device used. For example, a lead with eight electrodes may be selected for those with complex pain patterns or bilateral pain. Implantation of the spinal cord stimulator is typically a 2-step process. Initially, the electrode is temporarily implanted in the epidural space, allowing a trial period of stimulation. Once treatment effectiveness is confirmed (defined as at least 50% reduction in pain), the electrodes and radio-receiver/transducer are permanently implanted. Successful SCS may require extensive programming of the neurostimulators to identify the optimal electrode combinations and stimulation channels.

Dorsal Root Ganglion Neurostimulation

Dorsal root ganglion neurostimulation (or dorsal root ganglion stimulation, DRGS) uses the same epidural approach technique as spinal cord stimulation but targets a different anatomical target, the dorsal root ganglion. Dorsal root ganglia, situated within the spine as clusters of nerve cell bodies, serve as the "sensory gate" for pain signals entering the spinal cord. DRGS seeks to modulate the activity of these nerve cell bodies, potentially intercepting or diminishing pain signals before they reach the spinal cord. DRGS proves particularly efficacious for localized or chronic nerve pain conditions, such as complex regional pain syndrome, post-amputation pain, and pain following specific surgical procedures. It allows for more precise targeting of specific nerves and pain areas compared to SCS, potentially leading to better pain relief with fewer side effects. Moreover, DRGS may induce less paresthesia (tingling or numbness) than SCS, owing to its focused and precise stimulation. Recovery from DRGS implantation typically spans 6-8 weeks, during which individuals are advised to refrain from strenuous activities.

Traditional SCS devices use electrical stimulation with a frequency of 100 to 1000 Hz. High frequency devices use electrical stimulation with a frequency of 10,000 Hz. In 2016, the U.S. Food and Drug Administration (FDA) approved a clinician programmer application that allows a SCS device to provide stimulation in bursts rather than at a constant rate. Burst stimulation is proposed to relieve pain with fewer paresthesias. The burst stimulation device works in conjunction with standard SCS devices. With the newly approved app, stimulation is provided in five, 500-Hz burst spikes at a rate of 40 Hz, with a pulse width of 1 ms. Other neurostimulators target the dorsal root ganglion.

Summary of Evidence

Treatment-Refractory Chronic Pain

For individuals who have treatment-refractory chronic pain of the trunk or limbs who receive standard SCS, the evidence includes systematic reviews and randomized controlled trials (RCTs). Relevant outcomes are symptoms, functional outcomes, quality of life, medication use, and treatment-related morbidity. Available RCTs are heterogeneous regarding underlying diagnoses in select patient populations. However, the trials including individuals with underlying neuropathic pain processes have shown a significant benefit with SCS. Systematic reviews have supported the use of SCS to treat refractory trunk or limb pain, and individuals who have failed all other treatment modalities have few options. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have treatment-refractory chronic pain of the trunk or limbs who receive HFSCS, the evidence includes systematic reviews and RCTs. Relevant outcomes are symptoms, functional outcomes, quality of life, medication use, and treatment-related morbidity. Two RCTs that enrolled participants not previously treated with spinal cord stimulation reported clinically and statistically significant benefits associated with high-frequency spinal cord stimulation. Another RCT in individuals who had chronic pain despite previous treatment with standard SCS found no benefit for those receiving high-frequency stimulation compared with sham-control; however, it is difficult to compare these findings with other trials of SCS due to the different patient populations, short treatment periods, and the crossover period effect. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have treatment-refractory chronic pain of the trunk or limbs who receive dorsal root ganglion (DRG) neurostimulation, the evidence includes systematic reviews, an RCT, and case series. Relevant outcomes are symptoms, functional outcomes, quality of life,



medication use, and treatment-related morbidity. The unblinded RCT found that individuals receiving DRG neurostimulation had significantly higher rates of treatment success (physical functioning score and quality of life measures), at 3 and 12 months compared with those receiving standard SCS devices. DRG neurostimulation was found to be noninferior to SCS in the percentage achieving≥50% pain reduction, emotional functioning score, and 36-Item Short-Form Health Survey scores. Both groups experienced paresthesias but individuals in the DRG group reported less postural variation in paresthesia and reduced extraneous stimulation in nonpainful areas. Rates of serious adverse events were similar between the two study arms. The evidence is sufficient to determine that the technology results in an improvement in the net health outcome.

Critical Limb Ischemia

For individuals who have critical limb ischemia who receive SCS, the evidence includes systematic reviews of several small RCTs. Relevant outcomes are overall survival, symptoms, functional outcomes, quality of life, morbid events, hospitalizations, and treatment-related morbidity. In pooled analyses, SCS was associated with a lower risk of amputation versus control, but results were not consistently statistically significant due to differences in methodologies. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Treatment-Refractory Angina Pectoris

For individuals who have treatment-refractory angina pectoris who receive SCS, the evidence includes systematic reviews and RCTs. Relevant outcomes are overall survival, symptoms, functional outcomes, quality of life, morbid events, hospitalizations, and treatment-related morbidity. Numerous small RCTs have evaluated SCS as a treatment for refractory angina. While some have reported benefits, most have not. In two recent RCTs, there was no significant benefit in the primary outcomes. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Heart Failure

For individuals who have heart failure who receive spinal cord stimulation, the evidence includes a systematic review. Relevant outcomes are overall survival, symptoms, functional outcomes,



quality of life, morbid events, hospitalizations, and treatment-related morbidity. Four studies (including 2 RCTs) with a total of 125 patients were selected. Two studies reported improvements in New York Heart Association classification, and quality of life parameters, while only one study showed positive changes in left ventricular ejection function and VO2 max. No studies found significant changes in NT-proBNP (N-terminal Pro-Brain Natriuretic Peptide) following SCS therapy. Discrepancies in results could be due to methodological variations and induction technique diversity. Further studies are needed to develop a solid approach for employing SCS in heart failure patients.

Cancer-Related Pain

For individuals who have cancer-related pain who receive SCS, the evidence includes case series. Relevant outcomes are symptoms, functional outcomes, medication use, and treatment-related morbidity. No RCTs evaluating SCS in this population were identified. The evidence is insufficient to determine that the technology results in an improvement in the net health outcomes.

Ongoing and Unpublished Clinical Trials

Some currently ongoing and unpublished trials that might influence this review are listed in **Table 1**.

NCT No.	Trial Name	Planned	Completion
		Enrollment	Date
Ongoing			
NCT05466110	sPinal coRd stimulatiOn coMpared With Lumbar InStrumEntation for Low Back Pain After Previous Lumbar Decompression (PROMISE): a Prospective Randomized Controlled Study	84	May 2025
NCT04915157	Efficacy of Spinal Cord Stimulation in Patients With Refractory Angina Pectoris; a Randomized Controlled Trial	72	Jun 2025

Table 1. Summary of Key Trials

NCT No.	Trial Name	Planned	Completion
		Enrollment	Date
NCT05372822	Spinal Cord Burst Stimulation for Chronic Radicular Pain Following Lumbar Spine Surgery: A Randomized Double-blind Sham-controlled Crossover Trial	50	Aug 2025
NCT03681262	Comparing Long-Term Effectiveness of High Frequency and Burst Spinal Cord Stimulation	7	Dec 2026

NCT: national clinical trial.

^a Denotes industry-sponsored or cosponsored trial.

Practice Guidelines and Position Statements

The purpose of the following information is to provide reference material. Inclusion does not imply endorsement or alignment with the policy conclusions.

Guidelines or position statements will be considered for inclusion if they were issued by, or jointly by, a US professional society, an international society with US representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

American Association of Clinical Endocrinology

In 2022, the American Association of Clinical Endocrinology published evidence-based recommendations for the care of individuals with diabetes mellitus.⁸⁹ The guidelines state that 'Neuromodulatory techniques such as high-frequency spinal cord stimulation and combining pharmacological with nonpharmacological approaches should be considered in those with refractory painful DPN [diabetic peripheral neuropathy]'. The evidence for the statement was rated as Grade B [Strong]; BEL [best evidence level] 1 [Randomized controlled trial; Meta-analysis of only randomized controlled trials].

American Society of Regional Anesthesia and Pain Medicine

In 2023, American Society of Regional Anesthesia and Pain Medicine published evidence-based consensus guidelines on patient selection and trial stimulation for SCS therapy for chronic non-



cancer pain.⁹⁰ Recommendations included that SCS trial should be performed before a definitive SCS implant except in anginal pain (grade B). All patients must be screened with an objective validated instrument for psychosocial factors, and this must include depression (grade B). Despite some limitations, a trial helps patient selection and provides patients with an opportunity to experience the therapy. These recommendations are expected to guide practicing physicians and other stakeholders and should not be mistaken as practice standards. Physicians should continue to make their best judgment based on individual patient considerations and preferences.

American Society of Interventional Pain Physicians

In 2013, the American Society of Interventional Pain Physicians updated its evidence-based guidelines on interventional techniques for the management of chronic spinal pain.⁹¹ The guidelines included a statement that there is fair evidence for the following recommendation for SCS: "SCS is indicated in chronic low back pain with lower extremity pain secondary to failed back surgery syndrome (FBSS), after exhausting multiple conservative and interventional modalities". No updates have been made since the original publication.

American Society of Pain and Neuroscience

The American Society of Pain and Neuroscience issued a comprehensive guideline in 2021 on the management of cancer-related pain.⁹² The guideline found that spinal cord stimulation may be considered for 1) treatment of refractory cancer pain (Level II-3-C evidence: multiple series compared over time, with or without intervention, and surprising results in noncontrolled experience; treatment is neither recommendable nor inadvisable), and 2) on a case-by-case basis for "pain that is related to cancer treatment such as chemotherapy-induced peripheral neuropathy" (level III-C evidence: clinical experiences-based opinions, descriptive studies, clinical observations, or reports of expert committee; treatment is neither recommendable nor inadvisable).

The American Society of Pain and Neuroscience published consensus guidelines on interventional therapies for knee pain in 2022.⁹³ The guidelines state that "Chronic pain that is refractory to acute treatment is managed by progressing to spinal cord stimulator, dorsal root ganglion stimulator, or botulinum toxin (Botox) injection." They also include the statement that "DRG [Dorsal Root Ganglion Stimulation] is a safe and effective treatment option for chronic

post-surgical and focal neuropathic pain of the knee (i.e., complex regional pain syndrome [CRPS]); Level I, Grade A, Consensus Strong."

The American Society of Pain and Neuroscience published consensus guidelines on interventional therapies for back pain in 2022.⁹⁴ The guideline recommendations for spinal cord stimulation are summarized in Table 2 below.

Table 2. American Society of Pain and Neuroscience Recommendationsfor Spinal Cord Stimulation for Back Pain

Recommendation	Grade	Level of evidence	Level of certainty of net benefit
Following lumbar surgery	А	I-A	Strong
Treatment of non-surgical low back pain	В	I-C	Moderate
Treatment of lumbar spinal stenosis	С	I-C	Moderate

National Institute for Health and Care Excellence

In 2008, the NICE issued guidance on SCS for chronic pain of neuropathic or ischemic origin, which was reaffirmed in 2014.⁹⁵ The NICE recommended SCS as a treatment option for adults with chronic pain of neuropathic origin (measuring at least 50 mm on a 0-100 mm visual analog scale) that continues for at least 6 months despite appropriate conventional medical management, and who have had a successful trial of stimulation as part of an assessment by a specialist team.

In the same guidance, the NICE stated that SCS was not recommended for chronic pain of ischemic origin except in the context of research.

Medicare National Coverage

According to Medicare policy (Effective date 08/07/1995: Manual Section Number 160.7) the implantation of central nervous system stimulators may be covered as therapies for the relief of chronic intractable pain, subject to the following conditions:

- The implantation of the stimulator is used only as a late resort (if not a last resort) for individuals with chronic intractable pain;
- Other treatment modalities (pharmacological, surgical, physical, or psychological therapies) have been tried and did not prove satisfactory, or are judged to be unsuitable or contraindicated for the given individual;
- Individuals have undergone careful screening, evaluation, and diagnosis by a multidisciplinary team prior to implantation. (Such screening must include psychological, as well as physical evaluation.);
- All the facilities, equipment, and professional and support personnel required for the proper diagnosis, treatment training, and follow-up of the individual must be available; and
- Demonstration of pain relief with a temporarily implanted electrode precedes permanent implantation.⁹⁶

Regulatory Status

A large number of neurostimulator devices have been approved by the FDA through the premarket approval process under FDA product code: LGW (stimulator, spinal-cord, totally implanted for pain relief), PMP (Dorsal Root Ganglion Stimulator for Pain Relief), and GZB (Stimulator, Spinal-Cord, Implanted [Pain Relief]) (Table 5). In October 2016, the FDA approved BurstDR stimulation (St. Jude Medical), a clinician programmer application that provides intermittent "burst" stimulation for individuals with certain St. Jude spinal cord stimulation devices.

Table 5. FDA Cleared or Approved Devices for Spinal Cord and DorsalRoot Ganglion Stimulation



Device	Manufacture r	Produc t code	Original clearance/approva l date	Origina I 510(k) or PMA numbe r	Indication
Algovita Spinal Cord Stimulation System	Nuvectra Corporation	LGW	Nov 2015	P130028	Chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with failed back surgery syndrome, intractable low back pain, and leg pain.
Axium (1st generation) and Proclaim DRG (2nd generation) Neurostimulator System	Abbott Medical	РМР	Feb 2016	P150004	Moderate to severe chronic intractable pain of the lower limbs in adult patients with Types I and II CRPS
Cordis Programmable Neural Stimulator Models 900a	Cordis Corporation	LGW	Apr 1981ª	P800040	Stimulator, Spinal-Cord, Totally Implanted For Pain Relief
Freedom SCS	Stimwave Technologies (now Curonix)	GZB	Aug 2016	K180981	Chronic, intractable pain of the trunk and/or lower limbs, including unilateral or bilateral pain
Genesis And Eon Family Neurostimulatio n (Ipg) System;	St. Jude Medical/ Abbott Medical	LGW;QRB	Nov 2001	P010032	Chronic intractable pain of the trunk and/or limbs,



Device	Manufacture r	Produc t code	Original clearance/approva l date	Origina l 510(k) or PMA numbe r	Indication
Eterna Spinal Cord Stimulation (SCS) System; Prodigy, Proclaim, and Proclaim XR Spinal Cord Stimulation (SCS) Systems					including unilateral or bilateral pain associated with the following: failed back surgery syndrome, intractable low back and leg pain, and diabetic peripheral neuropathy of the lower extremities.
Restore, Itrel, Synergy, Intellis, And Vanta Spinal Cord Stimulation Systems	Medtronic Neuromodulation	LGW	Nov 1984	P840001	Chronic, intractable pain of the trunk and/or limbs- including unilateral or bilateral pain associated with the following conditions: • Failed Back Syndrome (FBS) or low back syndrome or failed back • Radicular pain syndrome or radiculopathies resulting in pain secondary to FBS or herniated disk

Device	Manufacture r	Produc t code	Original clearance/approva l date	Origina l 510(k) or PMA numbe r	Indication
				r	 Postlaminectom y pain Multiple back operations Unsuccessful disk surgery Refractory Degenerative Disk Disease (DDD)/herniated disk pain Peripheral causalgia Epidural fibrosis Arachnoiditis or lumbar adhesive arachnoiditis Complex Regional Pain Syndrome (CRPS), Reflex Sympathetic Dystrophy (RSD), or causalgia
					• Diabetic peripheral neuropathy of the lower extremities
Precision SCS System	Boston Scientific Corporation	LGW	Apr 2004	P030017	Chronic intractable pain of the trunk

Device	Manufacture r	Produc t code	Original clearance/approva l date	Origina l 510(k) or PMA numbe r	Indication
					and/or limbs, including unilateral or bilateral pain associated with failed back surgery syndrome, Types 1 and 2 CRPS, intractable low back pain and leg pain
Evoke SCS System	Saluda Medical Pty Ltd	LGW	Feb 2022	P190002	Chronic intractable pain of the trunk and/or limbs including unilateral or bilateral pain associated with the following: failed back surgery syndrome, intractable low back pain and leg pain.
Senza SCS System	Nevro Corporation	LGW	May 2015	P130022	Chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with the following: failed back surgery

Device	Manufacture r	Produc t code	Original clearance/approva l date	Origina I 510(k) or PMA numbe r	Indication
					syndrome, intractable low back pain, and leg pain. When programmed to include a frequency of 10 kHz:
		670	142010	//1020.47	Chronic intractable pain of the lower limbs, including unilateral or bilateral pain, associated with diabetic neuropathy; non-surgical refractory back pain (intractable back pain without prior surgery and not a candidate for back surgery)
Nalu Neurostimulatio n System	Nalu Medical, Inc	GZB	Mar 2019	K183047	Chronic, intractable pain of the trunk and/or limbs, including unilateral or bilateral pain
Prospera Spinal Cord Stimulation (SCS) System	Biotronik NRO, Inc	LGW	Mar 2023	P210037	Chronic, intractable pain in the trunk and/or limbs, which may

Device	Manufacture	Produc	Original	Origina	Indication
	r	t code	clearance/approva	l 510(k)	
			l date	or PMA	
				numbo	
				r	is all alla
					include
					bilateral nain
					resulting from
					any of the
					following: 1) FBS
					or low back
					syndrome or
					failed back: 2)
					Radicular pain
					syndrome or
					radiculopathies
					resulting in pain
					secondary to
					FBS or; 3)
					Herniated disk;
					4)
					Postlaminectom
					y pain; 5)
					Multiple back
					operations; 6)
					Unsuccessful
					disk surgery; 7)
					DDD/herniated
					disk pain
					refractory to
					conservative
					and surgical
					Interventions; δ)
					renpheral
					Causaigia, 9) Epidural
					fibrosis:10)
					Arachnoiditis or
					lumbar adhesive
					arachnoiditis:
					and 11) CRPS
					RSD, or
					causalgia

CRPS: Complex regional pain syndrome; DDD: degenerative disk disease; FDS failed back syndrome; :PMA: premarket approval; RSD: reflex sympathetic dystrophy; SCS: spinal cord stimulation. ^a Withdrawn in 2016¹

In September 2020, the FDA released a letter to healthcare providers reminding them to conduct a trial stimulation period before implanting a spinal cord stimulator as the agency continues to receive reports of serious adverse effects associated with these devices.² Between July 27, 2016 and July 27, 2020, the FDA received 107,728 medical device reports related to spinal cord simulators intended for pain including 497 associated with patient death, 77,937 with patient injury, and 29,924 with device malfunction. The most frequently reported patient problem codes were inadequate pain relief (28.1%), pain (15.2%), unexpected therapeutic effects (10.9%), infection (7.5%), and discomfort (5.9%). Additionally, the most frequently reported device problem codes were charging problems (11.2%), impedance (10.6%), migration (7.2%), battery problem (6.4%), and premature discharge of battery (4.2%). The FDA made the following recommendations for clinicians to consider:

- Conduct a trial stimulation as described in the device labeling to identify and confirm satisfactory pain relief before permanent implantation.
- Permanent spinal cord stimulation should only be implanted in individuals who have undergone and passed a stimulation trial.
- Providers typically perform a stimulation trial on an individual for 3 to 7 days, and success is usually defined by a 50% reduction in pain symptoms. Inform patients about the risks of serious side effects and what to expect during the trial stimulation.
- Before implantation of any spinal cord stimulation, discuss the benefits and risks of the different types of implants and other treatment options, including magnetic resonance imaging compatibility of the devices.
- Before implantation, provide individuals with the manufacturer's patient labeling and any other education materials for the device that will be implanted.
- Develop an individualized programming, treatment, and follow-up plan for spinal cord stimulation therapy delivery with each individual.
- Provide each individual with the name of the device manufacturer, model, and the unique device identifier of the implant received.

- 1. Food and Drug Administration. Cordis Programmable Neural Stimulator: Premarket Approval. Accessed May 6, 2025.
- 2. Turk DC, Dworkin RH, Allen RR, et al. Core outcome domains for chronic pain clinical trials: IMMPACT recommendations. Pain. Dec 2003; 106(3): 337-345. PMID 14659516
- Dworkin RH, Turk DC, Farrar JT, et al. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain. Jan 2005; 113(1-2): 9-19. PMID 15621359
- 4. Dworkin RH, Turk DC, Wyrwich KW, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain. Feb 2008; 9(2): 105-21. PMID 18055266
- Kerns RD, Turk DC, Rudy TE. The West Haven-Yale Multidimensional Pain Inventory (WHYMPI). Pain. Dec 1985; 23(4): 345-356. PMID 4088697
- Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singap. Mar 1994; 23(2): 129-38. PMID 8080219
- Fairbank JC, Pynsent PB. The Oswestry Disability Index. Spine (Phila Pa 1976). Nov 15 2000; 25(22): 2940-52; discussion 2952. PMID 11074683
- Ostelo RW, Deyo RA, Stratford P, et al. Interpreting change scores for pain and functional status in low back pain: towards international consensus regarding minimal important change. Spine (Phila Pa 1976). Jan 01 2008; 33(1): 90-4. PMID 18165753
- 9. Wells GA, Tugwell P, Kraag GR, et al. Minimum important difference between patients with rheumatoid arthritis: the patient's perspective. J Rheumatol. Mar 1993; 20(3): 557-60. PMID 8478873
- Kosinski M, Zhao SZ, Dedhiya S, et al. Determining minimally important changes in generic and disease-specific healthrelated quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthritis Rheum. Jul 2000; 43(7): 1478-87. PMID 10902749
- 11. Angst F, Aeschlimann A, Stucki G. Smallest detectable and minimal clinically important differences of rehabilitation intervention with their implications for required sample sizes using WOMAC and SF-36 quality of life measurement instruments in patients with osteoarthritis of the lower extremities. Arthritis Rheum. Aug 2001; 45(4): 384-91. PMID 11501727
- 12. Beck ATS, R.A. Beck Depression Inventory. San Antonio, TX: Psychological Corporation; 1993.
- 13. Curran SL, Andrykowski MA, Studts JL. Short Form of the Profile of Mood States (POMS-SF): Psychometric information. Psychol Assess 1995;7:80-83.
- 14. Visnjevac O, Costandi S, Patel BA, et al. A Comprehensive Outcome-Specific Review of the Use of Spinal Cord Stimulation for Complex Regional Pain Syndrome. Pain Pract. Apr 2017; 17(4): 533-545. PMID 27739179
- 15. O'Connell NE, Wand BM, McAuley J, et al. Interventions for treating pain and disability in adults with complex regional pain syndrome. Cochrane Database Syst Rev. Apr 30 2013; 2013(4): CD009416. PMID 23633371
- 16. Grider JS, Manchikanti L, Carayannopoulos A, et al. Effectiveness of Spinal Cord Stimulation in Chronic Spinal Pain: A Systematic Review. Pain Physician. Jan 2016; 19(1): E33-54. PMID 26752493

- 17. Traeger AC, Gilbert SE, Harris IA, et al. Spinal cord stimulation for low back pain. Cochrane Database Syst Rev. Mar 07 2023; 3(3): CD014789. PMID 36878313
- Head J, Mazza J, Sabourin V, et al. Waves of Pain Relief: A Systematic Review of Clinical Trials in Spinal Cord Stimulation Waveforms for the Treatment of Chronic Neuropathic Low Back and Leg Pain. World Neurosurg. Nov 2019; 131: 264-274.e3. PMID 31369885
- Duarte RV, Nevitt S, Maden M, et al. Spinal cord stimulation for the management of painful diabetic neuropathy: a systematic review and meta-analysis of individual patient and aggregate data. Pain. Nov 01 2021; 162(11): 2635-2643.
 PMID 33872236
- 20. Henson JV, Varhabhatla NC, Bebic Z, et al. Spinal Cord Stimulation for Painful Diabetic Peripheral Neuropathy: A Systematic Review. Pain Ther. Dec 2021; 10(2): 895-908. PMID 34244979
- 21. Raghu ALB, Parker T, Aziz TZ, et al. Invasive Electrical Neuromodulation for the Treatment of Painful Diabetic Neuropathy: Systematic Review and Meta-Analysis. Neuromodulation. Jan 2021; 24(1): 13-21. PMID 32588933
- 22. Strand NH, Burkey AR. Neuromodulation in the Treatment of Painful Diabetic Neuropathy: A Review of Evidence for Spinal Cord Stimulation. J Diabetes Sci Technol. Mar 2022; 16(2): 332-340. PMID 34842478
- 23. Hoelzer BC, Edgar D, Lu SP, et al. Indirect Comparison of 10 kHz Spinal Cord Stimulation (SCS) versus Traditional Low-Frequency SCS for the Treatment of Painful Diabetic Neuropathy: A Systematic Review of Randomized Controlled Trials. Biomedicines. Oct 19 2022; 10(10). PMID 36289892
- 24. O'Connell NE, Ferraro MC, Gibson W, et al. Implanted spinal neuromodulation interventions for chronic pain in adults. Cochrane Database Syst Rev. Dec 02 2021; 12(12): CD013756. PMID 34854473
- Zhou M, Zhong H, Xing C, et al. Comparison of clinical outcomes associated with spinal cord stimulation (SCS) or conventional medical management (CMM) for chronic pain: a systematic review and meta-analysis. Eur Spine J. Jun 2023; 32(6): 2029-2041. PMID 37067600
- 26. Huygen FJPM, Soulanis K, Rtveladze K, et al. Spinal Cord Stimulation vs Medical Management for Chronic Back and Leg Pain: A Systematic Review and Network Meta-Analysis. JAMA Netw Open. Nov 04 2024; 7(11): e2444608. PMID 39541119
- 27. North RB, Kidd DH, Farrokhi F, et al. Spinal cord stimulation versus repeated lumbosacral spine surgery for chronic pain: a randomized, controlled trial. Neurosurgery. 2005; 56(1): 98-106; discussion 106-7. PMID 15617591
- Kumar K, Taylor RS, Jacques L, et al. Spinal cord stimulation versus conventional medical management for neuropathic pain: a multicentre randomised controlled trial in patients with failed back surgery syndrome. Pain. Nov 2007; 132(1-2): 179-88. PMID 17845835
- Kumar K, Taylor RS, Jacques L, et al. The effects of spinal cord stimulation in neuropathic pain are sustained: a 24-month follow-up of the prospective randomized controlled multicenter trial of the effectiveness of spinal cord stimulation. Neurosurgery. Oct 2008; 63(4): 762-70; discussion 770. PMID 18981888
- 30. Kemler MA, Barendse GA, van Kleef M, et al. Spinal cord stimulation in patients with chronic reflex sympathetic dystrophy. N Engl J Med. Aug 31 2000; 343(9): 618-24. PMID 10965008
- 31. Kemler MA, De Vet HC, Barendse GA, et al. The effect of spinal cord stimulation in patients with chronic reflex sympathetic dystrophy: two years' follow-up of the randomized controlled trial. Ann Neurol. Jan 2004; 55(1): 13-8. PMID 14705107
- Kemler MA, de Vet HC, Barendse GA, et al. Effect of spinal cord stimulation for chronic complex regional pain syndrome Type I: five-year final follow-up of patients in a randomized controlled trial. J Neurosurg. Feb 2008; 108(2): 292-8. PMID 18240925

- 33. Slangen R, Schaper NC, Faber CG, et al. Spinal cord stimulation and pain relief in painful diabetic peripheral neuropathy: a prospective two-center randomized controlled trial. Diabetes Care. Nov 2014; 37(11): 3016-24. PMID 25216508
- 34. de Vos CC, Meier K, Zaalberg PB, et al. Spinal cord stimulation in patients with painful diabetic neuropathy: a multicentre randomized clinical trial. Pain. Nov 2014; 155(11): 2426-31. PMID 25180016
- 35. Duarte RV, Andronis L, Lenders MW, et al. Quality of life increases in patients with painful diabetic neuropathy following treatment with spinal cord stimulation. Qual Life Res. Jul 2016; 25(7): 1771-7. PMID 26694963
- 36. Rigoard P, Basu S, Desai M, et al. Multicolumn spinal cord stimulation for predominant back pain in failed back surgery syndrome patients: a multicenter randomized controlled trial. Pain. Jun 2019; 160(6): 1410-1420. PMID 30720582
- Zuidema X, van Daal E, van Geel I, et al. Long-Term Evaluation of Spinal Cord Stimulation in Patients With Painful Diabetic Polyneuropathy: An Eight-to-Ten-Year Prospective Cohort Study. Neuromodulation. Jul 2023; 26(5): 1074-1080. PMID 36587999
- Mekhail N, Levy RM, Deer TR, et al. Long-term safety and efficacy of closed-loop spinal cord stimulation to treat chronic back and leg pain (Evoke): a double-blind, randomised, controlled trial. Lancet Neurol. Feb 2020; 19(2): 123-134. PMID 31870766
- Mekhail NA, Levy RM, Deer TR, et al. ECAP-controlled closed-loop versus open-loop SCS for the treatment of chronic pain: 36-month results of the EVOKE blinded randomized clinical trial. Reg Anesth Pain Med. May 07 2024; 49(5): 346-354. PMID 37640452
- 40. Rauck RL, Loudermilk E, Thomson SJ, et al. Long-term safety of spinal cord stimulation systems in a prospective, global registry of patients with chronic pain. Pain Manag. Feb 2023; 13(2): 115-127. PMID 36691862
- 41. Mekhail NA, Mathews M, Nageeb F, et al. Retrospective review of 707 cases of spinal cord stimulation: indications and complications. Pain Pract. 2011; 11(2): 148-53. PMID 21371254
- 42. Hou S, Kemp K, Grabois M. A Systematic Evaluation of Burst Spinal Cord Stimulation for Chronic Back and Limb Pain. Neuromodulation. Jun 2016; 19(4): 398-405. PMID 27139915
- 43. Deer T, Heros R, Tavel E, et al. Comparing Conventional Medical Management to Spinal Cord Stimulation for the Treatment of Low Back Pain in a Cohort of DISTINCT RCT Patients. J Pain Res. 2024; 17: 2741-2752. PMID 39193462
- 44. De Ridder D, Plazier M, Kamerling N, et al. Burst spinal cord stimulation for limb and back pain. World Neurosurg. Nov 2013; 80(5): 642-649.e1. PMID 23321375
- 45. De Ridder D, Vanneste S, Plazier M, et al. Burst spinal cord stimulation: toward paresthesia-free pain suppression. Neurosurgery. May 2010; 66(5): 986-90. PMID 20404705
- 46. Schu S, Slotty PJ, Bara G, et al. A prospective, randomised, double-blind, placebo-controlled study to examine the effectiveness of burst spinal cord stimulation patterns for the treatment of failed back surgery syndrome. Neuromodulation. Jul 2014; 17(5): 443-50. PMID 24945621
- Kriek N, Groeneweg JG, Stronks DL, et al. Preferred frequencies and waveforms for spinal cord stimulation in patients with complex regional pain syndrome: A multicentre, double-blind, randomized and placebo-controlled crossover trial. Eur J Pain. Mar 2017; 21(3): 507-519. PMID 27714945
- Deer T, Slavin KV, Amirdelfan K, et al. Success Using Neuromodulation With BURST (SUNBURST) Study: Results From a Prospective, Randomized Controlled Trial Using a Novel Burst Waveform. Neuromodulation. Jan 2018; 21(1): 56-66. PMID 28961366

- 49. Eldabe S, Duarte R, Gulve A, et al. Analgesic Efficacy of "Burst" and Tonic (500 Hz) Spinal Cord Stimulation Patterns: A Randomized Placebo-Controlled Crossover Study. Neuromodulation. Apr 2021; 24(3): 471-478. PMID 33251662
- Hara S, Andresen H, Solheim O, et al. Effect of Spinal Cord Burst Stimulation vs Placebo Stimulation on Disability in Patients With Chronic Radicular Pain After Lumbar Spine Surgery: A Randomized Clinical Trial. JAMA. Oct 18 2022; 328(15): 1506-1514. PMID 36255427
- 51. Deer T, Gilligan C, Falowski S, et al. Treatment of Refractory Low Back Pain Using Passive Recharge Burst in Patients Without Options for Corrective Surgery: Findings and Results From the DISTINCT Study, a Prospective Randomized Multicenter Controlled Trial. Neuromodulation. Oct 2023; 26(7): 1387-1399. PMID 37642628
- 52. Sun S, Yin J, Wei H, et al. Long-Term Efficacy and Safety of High-Frequency Spinal Stimulation for Chronic Pain: A Meta-Analysis of Randomized Controlled Trials. Clin J Pain. Jul 01 2024; 40(7): 415-427. PMID 38595082
- 53. Bicket MC, Dunn RY, Ahmed SU. High-Frequency Spinal Cord Stimulation for Chronic Pain: Pre-Clinical Overview and Systematic Review of Controlled Trials. Pain Med. Dec 2016; 17(12): 2326-2336. PMID 28025366
- 54. Perruchoud C, Eldabe S, Batterham AM, et al. Analgesic efficacy of high-frequency spinal cord stimulation: a randomized double-blind placebo-controlled study. Neuromodulation. 2013; 16(4): 363-9; discussion 369. PMID 23425338
- Kapural L, Yu C, Doust MW, et al. Novel 10-kHz High-frequency Therapy (HF10 Therapy) Is Superior to Traditional Lowfrequency Spinal Cord Stimulation for the Treatment of Chronic Back and Leg Pain: The SENZA-RCT Randomized Controlled Trial. Anesthesiology. Oct 2015; 123(4): 851-60. PMID 26218762
- 56. Petersen EA, Stauss TG, Scowcroft JA, et al. Effect of High-frequency (10-kHz) Spinal Cord Stimulation in Patients With Painful Diabetic Neuropathy: A Randomized Clinical Trial. JAMA Neurol. Jun 01 2021; 78(6): 687-698. PMID 33818600
- 57. Bolash R, Creamer M, Rauck R, et al. Wireless High-Frequency Spinal Cord Stimulation (10 kHz) Compared with Multiwaveform Low-Frequency Spinal Cord Stimulation in the Management of Chronic Pain in Failed Back Surgery Syndrome Subjects: Preliminary Results of a Multicenter, Prospective Randomized Controlled Study. Pain Med. Oct 01 2019; 20(10): 1971-1979. PMID 30908577
- 58. De Andres J, Monsalve-Dolz V, Fabregat-Cid G, et al. Prospective, Randomized Blind Effect-on-Outcome Study of Conventional vs High-Frequency Spinal Cord Stimulation in Patients with Pain and Disability Due to Failed Back Surgery Syndrome. Pain Med. Dec 01 2017; 18(12): 2401-2421. PMID 29126228
- Petersen EA, Stauss TG, Scowcroft JA, et al. Durability of High-Frequency 10-kHz Spinal Cord Stimulation for Patients With Painful Diabetic Neuropathy Refractory to Conventional Treatments: 12-Month Results From a Randomized Controlled Trial. Diabetes Care. Jan 01 2022; 45(1): e3-e6. PMID 34844993
- 60. Kapural L, Yu C, Doust MW, et al. Comparison of 10-kHz High-Frequency and Traditional Low-Frequency Spinal Cord Stimulation for the Treatment of Chronic Back and Leg Pain: 24-Month Results From a Multicenter, Randomized, Controlled Pivotal Trial. Neurosurgery. Nov 2016; 79(5): 667-677. PMID 27584814
- Kapural L, Jameson J, Johnson C, et al. Treatment of nonsurgical refractory back pain with high-frequency spinal cord stimulation at 10 kHz: 12-month results of a pragmatic, multicenter, randomized controlled trial. J Neurosurg Spine. Aug 01 2022; 37(2): 188-199. PMID 35148512
- Petersen EA, Stauss TG, Scowcroft JA, et al. High-Frequency 10-kHz Spinal Cord Stimulation Improves Health-Related Quality of Life in Patients With Refractory Painful Diabetic Neuropathy: 12-Month Results From a Randomized Controlled Trial. Mayo Clin Proc Innov Qual Outcomes. Aug 2022; 6(4): 347-360. PMID 35814185
- 63. Petersen EA, Stauss TG, Scowcroft JA, et al. Long-term efficacy of high-frequency (10 kHz) spinal cord stimulation for the treatment of painful diabetic neuropathy: 24-Month results of a randomized controlled trial. Diabetes Res Clin Pract. Sep 2023; 203: 110865. PMID 37536514

- 64. Patel NP, Jameson J, Johnson C, et al. Durable responses at 24 months with high-frequency spinal cord stimulation for nonsurgical refractory back pain. J Neurosurg Spine. Feb 01 2024; 40(2): 229-239. PMID 37976509
- 65. Campos-Fajardo S, Sierra-Peña JA, Suárez-Monsalve S, et al. Effectiveness of Dorsal Root Ganglion Stimulation in Chronic Pain Management: A Systematic Review. World Neurosurg. Oct 2024; 190: 157-171. PMID 38945208
- 66. Mattie R, Lin AB, Bhandal H, et al. Spinal cord stimulation for the treatment of complex regional pain syndrome: A systematic review of randomized controlled trials. Interv Pain Med. Dec 2024; 3(4): 100527. PMID 39717450
- 67. Vuka I, Marciuš T, Došenović S, et al. Neuromodulation with electrical field stimulation of dorsal root ganglion in various pain syndromes: a systematic review with focus on participant selection. J Pain Res. 2019; 12: 803-830. PMID 30881093
- 68. Deer TR, Hunter CW, Mehta P, et al. A Systematic Literature Review of Dorsal Root Ganglion Neurostimulation for the Treatment of Pain. Pain Med. Aug 01 2020; 21(8): 1581-1589. PMID 32803221
- 69. Moman RN, Peterson AA, Maher DP, et al. Infectious Complications of Dorsal Root Ganglion Stimulation: A Systematic Review and Pooled Analysis of Incidence. Neuromodulation. Oct 2022; 25(7): 956-964. PMID 34096135
- 70. D'Souza RS, Kubrova E, Her YF, et al. Dorsal Root Ganglion Stimulation for Lower Extremity Neuropathic Pain Syndromes: An Evidence-Based Literature Review. Adv Ther. Oct 2022; 39(10): 4440-4473. PMID 35994195
- Deer TR, Levy RM, Kramer J, et al. Dorsal root ganglion stimulation yielded higher treatment success rate for complex regional pain syndrome and causalgia at 3 and 12 months: a randomized comparative trial. Pain. Apr 2017; 158(4): 669-681. PMID 28030470
- 72. Food and Drug Administration. Summary of Safety and Effectiveness Data (SSED): Axium Neurostimulator System. 2016; https://www.accessdata.fda.gov/cdrh_docs/pdf15/P150004b.pdf. Accessed March 11, 2025.
- 73. Mekhail N, Deer TR, Kramer J, et al. Paresthesia-Free Dorsal Root Ganglion Stimulation: An ACCURATE Study Sub-Analysis. Neuromodulation. Feb 2020; 23(2): 185-195. PMID 30861286
- 74. Deer T, Pope J, Hunter C, et al. Safety Analysis of Dorsal Root Ganglion Stimulation in the Treatment of Chronic Pain. Neuromodulation. Feb 2020; 23(2): 239-244. PMID 30861617
- 75. Sivanesan E, Bicket MC, Cohen SP. Retrospective analysis of complications associated with dorsal root ganglion stimulation for pain relief in the FDA MAUDE database. Reg Anesth Pain Med. Jan 2019; 44(1): 100-106. PMID 30640660
- 76. Weiner RL, Yeung A, Montes Garcia C, et al. Treatment of FBSS Low Back Pain with a Novel Percutaneous DRG Wireless Stimulator: Pilot and Feasibility Study. Pain Med. Oct 2016; 17(10): 1911-1916. PMID 27125284
- 77. Ubbink DT, Vermeulen H. Spinal cord stimulation for non-reconstructable chronic critical leg ischaemia. Cochrane Database Syst Rev. Feb 28 2013; 2013(2): CD004001. PMID 23450547
- 78. Klomp HM, Steyerberg EW, Habbema JD, et al. What is the evidence on efficacy of spinal cord stimulation in (subgroups of) patients with critical limb ischemia?. Ann Vasc Surg. 2009; 23(3): 355-63. PMID 19128928
- 79. Klomp HM, Spincemaille GH, Steyerberg EW, et al. Spinal-cord stimulation in critical limb ischaemia: a randomised trial. ESES Study Group. Lancet. Mar 27 1999; 353(9158): 1040-4. PMID 10199350
- 80. Abu Dabrh AM, Steffen MW, Asi N, et al. Nonrevascularization-based treatments in patients with severe or critical limb ischemia. J Vasc Surg. Nov 2015; 62(5): 1330-9.e13. PMID 26409842
- 81. Pan X, Bao H, Si Y, et al. Spinal Cord Stimulation for Refractory Angina Pectoris: A Systematic Review and Meta-analysis. Clin J Pain. Jun 2017; 33(6): 543-551. PMID 27875377



- 82. Tsigaridas N, Naka K, Tsapogas P, et al. Spinal cord stimulation in refractory angina. A systematic review of randomized controlled trials. Acta Cardiol. Apr 2015; 70(2): 233-43. PMID 26148385
- 83. Zipes DP, Svorkdal N, Berman D, et al. Spinal cord stimulation therapy for patients with refractory angina who are not candidates for revascularization. Neuromodulation. 2012; 15(6): 550-8; discussion 558-9. PMID 22494013
- 84. Lanza GA, Grimaldi R, Greco S, et al. Spinal cord stimulation for the treatment of refractory angina pectoris: a multicenter randomized single-blind study (the SCS-ITA trial). Pain. Jan 2011; 152(1): 45-52. PMID 21084162
- 85. Lanza GA, Barone L, Di Monaco A. Effect of spinal cord stimulation in patients with refractory angina: evidence from observational studies. Neuromodulation. 2012; 15(6): 542-9; disdcussion 549. PMID 22364309
- 86. Ashrafpour S, Ashrafpour M. Efficacy of spinal cord stimulation as an adjunctive therapy in heart failure: A systematic review. Neurophysiol Clin. May 2024; 54(3): 102945. PMID 38422720
- 87. Lihua P, Su M, Zejun Z, et al. Spinal cord stimulation for cancer-related pain in adults. Cochrane Database Syst Rev. Feb 28 2013; (2): CD009389. PMID 23450600
- Peng L, Min S, Zejun Z, et al. Spinal cord stimulation for cancer-related pain in adults. Cochrane Database Syst Rev. Jun 29 2015; 2015(6): CD009389. PMID 26121600
- Blonde L, Umpierrez GE, Reddy SS, et al. American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. Endocr Pract. Oct 2022; 28(10): 923-1049. PMID 35963508
- Shanthanna H, Eldabe S, Provenzano DA, et al. Evidence-based consensus guidelines on patient selection and trial stimulation for spinal cord stimulation therapy for chronic non-cancer pain. Reg Anesth Pain Med. Jun 2023; 48(6): 273-287. PMID 37001888
- 91. Manchikanti L, Abdi S, Atluri S, et al. An update of comprehensive evidence-based guidelines for interventional techniques in chronic spinal pain. Part II: guidance and recommendations. Pain Physician. Apr 2013; 16(2 Suppl): S49-283. PMID 23615883
- 92. Aman MM, Mahmoud A, Deer T, et al. The American Society of Pain and Neuroscience (ASPN) Best Practices and Guidelines for the Interventional Management of Cancer-Associated Pain. J Pain Res. 2021; 14: 2139-2164. PMID 34295184
- 93. Hunter CW, Deer TR, Jones MR, et al. Consensus Guidelines on Interventional Therapies for Knee Pain (STEP Guidelines) from the American Society of Pain and Neuroscience. J Pain Res. 2022; 15: 2683-2745. PMID 36132996
- 94. Sayed D, Grider J, Strand N, et al. The American Society of Pain and Neuroscience (ASPN) Evidence-Based Clinical Guideline of Interventional Treatments for Low Back Pain. J Pain Res. 2022; 15: 3729-3832. PMID 36510616
- National Institute for Health and Care Excellence (NICE). Spinal cord stimulation for chronic pain of neuropathic or ischaemic origin [TA159]. 2008; https://www.nice.org.uk/guidance/ta159. Accessed May 6, 2025.
- Centers for Medicare and Medicaid Services. National Coverage Determination (NCD) for Electrical Nerve Stimulators (160.7). 1995; https://www.cms.gov/medicare-coverage-database/details/ncddetails.aspx?NCDId=240&ncdver=1&bc=AAAAgAAAAAA&. Accessed May 6, 2025.

History

Date	Comments
04/10/12	New policy replacing 7.01.25.
07/20/12	Clarification made to first policy statement; pain is defined in single nerve-root distribution change to lumbosacral nerve root distribution, as approved by MPC on April 10, 2012.
08/27/12	Update Related Policies – Add 7.01.20. Update Coding Section – ICD-10 codes are now effective 10/01/2014.
04/16/13	Replace policy. No change to policy statements. References 14, 18, 21, 22 added.
12/19/13	Update Related Policies. Remove 1.01.19 as it was archived.
07/14/14	Annual Review. Policy statement revised. Spinal cord stimulation may now be considered medically necessary for pain due to complex regional pain syndrome when criteria are met. "Lumbar" added as clarification to failed back surgery syndrome and criteria revised. Rationale extensively updated. References added.
03/31/15	Annual Review. Policy statements unchanged. Policy updated with literature review through December 2014. References 5. 6, 16 added. Remove ICD-9 codes 03.93, 03.94, 86.05, 86.09 and 86.94, along with associated ICD-10 codes; these do not suspend and are informational only.
05/27/15	Coding update; ICD-9 procedure code 86.96 added to policy; ICD-10 PCS codes adding per cross walk remediation.
01/29/16	Coding update. Added HCPCS code L8679.
05/01/16	Annual Review, approved April 12, 2016. Clarified policy statement adding, licensed mental health provider. No new references added.
03/01/17	Coding Update. Removed CPT code 95973 as it was deleted as of 01/01/2016.
04/14/17	Policy moved into new format; no change to policy statements. Evidence Review section reformatted.
07/01/17	Interim Review, approved June 6, 2017. Minor update to Medically Necessary policy statement to include Demonstration of at least 50% pain relief with a temporarily implanted electrode that was placed at least 3 days before the permanent implantation. Added HCPCS code L8683.
08/25/17	Coding update, removed CPT codes 95970, 95971, and 95972.
10/01/17	Annual Review, approved September 12, 2017. Policy section updated with the inclusion of high-frequency stimulation, high frequency with burst, and dorsal root ganglion stimulators. Title changed to include dorsal root ganglion stimulators. New HCPCS codes added. Removed CPT codes 95970, 95971, and 95972. Replacement and upgrade device criteria added. References 13, 17, 19-25, 30 and 40 added.
02/01/18	Interim Review, approved January 16, 2018. Added levels for spinal cord stimulator lead placement for clarity. Modified policy statement for clarity regarding trial and

Date	Comments
	permanent implantation of a SCS. Removed axial back pain, failed cervical and thoracic surgery, post herpetic neuralgia, occipital neuralgia, and peripheral neuropathy from the investigational indications and added treatment of cancer-related pain, treatment of heart failure and pelvic pain added to investigational indications. Reference added.
02/06/18	Coding update, removed HCPCS code C1822.
02/13/18	Minor update; updated Introduction section.
03/01/18	Note added that this policy has been revised. Added link to revised policy that will become effective June 1, 2018.
06/01/18	Minor update; removed note and link to updated policy. Surgery Site of Service criteria becomes effective.
07/01/18	Annual Review, approved June 22, 2018. Policy updated with literature review through February 2018; references 1-12, 18-19, 21, 34-35, and 40-42 added. Policy statements unchanged. Related Information section revised to add burst neurostimulation as an alternate programming of a standard SCS device.
05/01/19	Minor update, clarified Site of Service requirements.
07/01/19	Annual Review, approved June 11, 2019. Policy updated with literature review through March 2019; references added. The dorsal root ganglion (DRG) policy statement was changed from investigational to medically necessary: "Dorsal root ganglion neurostimulation is considered medically necessary for the treatment of severe and chronic pain of the trunk or limbs." Removed HCPCS code L8684.
04/01/20	Delete policy, approved March 10, 2020. This policy will be deleted effective July 2, 2020 and replaced with InterQual criteria for dates of service on or after July 2, 2020.
07/02/20	Delete policy.
11/01/20	Policy reinstated effective February 5, 2021, approved October 13, 2020. Policy updated with literature review through February 2020; references added. Policy statements unchanged. Added HCPCS C1767, C1778, C1787, C1820, C1822, C1883 and C1897.
07/01/21	Annual Review, approved June 1, 2021. Policy updated with literature review through March 11, 2021; references added. Policy statements unchanged.
07/01/22	Annual Review, approved June 27, 2022. Policy updated with literature review through February 16, 2022; references added. Policy statements unchanged except for minor clarification.
01/01/23	Coding update. Added new HCPC codes C1826 and C1827.
07/01/23	Annual Review, approved June 12, 2023. Policy updated with literature review through February 13, 2023; references added. Policy statements unchanged. Changed the wording from "patient" to "individual" throughout the policy for standardization.
01/01/24	Coding update. Added new CPT codes 0784T and 0785T.

Date	Comments
07/01/24	Annual Review, approved June 24, 2024. Policy updated with literature review through February 27, 2024; references added. Policy statements unchanged.
07/01/25	Annual Review, approved June 23, 2025. Policy updated with literature review through March 12, 2025; references added. Policy statements unchanged.

Disclaimer: This medical policy is a guide in evaluating the medical necessity of a particular service or treatment. The Company adopts policies after careful review of published peer-reviewed scientific literature, national guidelines and local standards of practice. Since medical technology is constantly changing, the Company reserves the right to review and update policies as appropriate. Member contracts differ in their benefits. Always consult the member benefit booklet or contact a member service representative to determine coverage for a specific medical service or supply. CPT codes, descriptions and materials are copyrighted by the American Medical Association (AMA). ©2025 Premera All Rights Reserved.

Scope: Medical policies are systematically developed guidelines that serve as a resource for Company staff when determining coverage for specific medical procedures, drugs or devices. Coverage for medical services is subject to the limits and conditions of the member benefit plan. Members and their providers should consult the member benefit booklet or contact a customer service representative to determine whether there are any benefit limitations applicable to this service or supply. This medical policy does not apply to Medicare Advantage.

